MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
30.49
+1.94
+6.80%
After Hours: 30.63 +0.14 +0.46% 19:59 02/12 EST
OPEN
33.75
PREV CLOSE
28.55
HIGH
34.38
LOW
30.18
VOLUME
8.59M
TURNOVER
--
52 WEEK HIGH
43.15
52 WEEK LOW
18.92
MARKET CAP
3.45B
P/E (TTM)
-14.3943
1D
5D
1M
3M
1Y
5Y
1D
Viking Therapeutics Bets Big on Obesity Breakthroughs
TipRanks · 6h ago
Stocks Plunge on Tech Weakness and AI Fears
NASDAQ · 7h ago
If You Invested $100 In Viking Therapeutics Stock 10 Years Ago, You Would Have This Much Today
Benzinga · 10h ago
BUZZ-U.S. STOCKS ON THE MOVE-FedEx Corp, Lincoln National
Reuters · 11h ago
Viking Therapeutics Stock Soars: What's Driving The Momentum?
Benzinga · 14h ago
HubSpot, Crocs, Zebra Technologies, Trinity Industries And Other Big Stocks Moving Higher On Thursday
Benzinga · 14h ago
BUZZ-U.S. STOCKS ON THE MOVE-Iron Mountain, BridgeBio, Old Dominion, 
Reuters · 14h ago
Jefferies Keeps Their Buy Rating on Viking Therapeutics (VKTX)
TipRanks · 15h ago
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.